Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe.
OBJECTIVE:The aim of the present study is to examine how moderate-to-severe ulcerative colitis (UC) is currently managed in real-world clinical practice across the United States (US) and European Union Five (EU5; France, Germany, Italy, Spain, and the United Kingdom). METHODS:Data from the 2017 Adel...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0227914 |
| _version_ | 1819021778211569664 |
|---|---|
| author | Alessandro Armuzzi Marco daCosta DiBonaventura Miriam Tarallo James Lucas Daniel Bluff Benjamin Hoskin Danielle Bargo Joseph C Cappelleri Daniel Quirk Leonardo Salese |
| author_facet | Alessandro Armuzzi Marco daCosta DiBonaventura Miriam Tarallo James Lucas Daniel Bluff Benjamin Hoskin Danielle Bargo Joseph C Cappelleri Daniel Quirk Leonardo Salese |
| author_sort | Alessandro Armuzzi |
| collection | DOAJ |
| description | OBJECTIVE:The aim of the present study is to examine how moderate-to-severe ulcerative colitis (UC) is currently managed in real-world clinical practice across the United States (US) and European Union Five (EU5; France, Germany, Italy, Spain, and the United Kingdom). METHODS:Data from the 2017 Adelphi Inflammatory Bowel-Disease Specific Programme (IBD-DSP) were used. The IBD-DSP is a database of patient chart information abstracted by selected gastroenterologists across the US and EU5. Eligible gastroenterologists who agreed to participate were asked to complete patient record forms for the next seven consecutive eligible adult patients with UC. Only charts from patients with moderate-to-severe UC were included in the analysis (defined as those with documented administration of either an immunosuppressant [IM] or a biologic). Treatment patterns were reported descriptively. RESULTS:411 and 1191 patient charts were included in the US and EU5 (mean ages 44.2 and 39.6 years; 53.0% and 43.5% female), respectively. For those with complete treatment history, 40.7% and 52.9% used either an IM or biologic as their first treatment (with or without steroids). Usage of these therapies increased in subsequent lines. The percentage of patients treated with combination therapy (i.e., biologic therapy with a concomitant IM) in first line generally varied between 10-20% (e.g., US: adalimumab (ADA), 10.8%; infliximab (IFX), 18.2%; EU5: ADA, 12.5%; IFX, 19.9%), though increased in later lines in the EU5. Among patients currently using a biologic therapy, between 10-40% of patients used a higher than indicated dose or greater than indicated dosing frequency during maintenance (e.g., US: IFX, 37.1%; ADA, 13.4%; EU5: IFX, 39.1%; ADA, 36.1%). In both the US and EU5, the primary reason for switching therapy was efficacy-related. CONCLUSIONS:In this analysis, many patients with moderate-to-severe UC use an IM or biologic as their first therapy after diagnosis. Combination therapy and dose escalation are also common, and underscore the challenges with managing this patient population. |
| first_indexed | 2024-12-21T04:12:30Z |
| format | Article |
| id | doaj.art-92dd4570321c481395ff3b2d04d21738 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T04:12:30Z |
| publishDate | 2020-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-92dd4570321c481395ff3b2d04d217382022-12-21T19:16:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01151e022791410.1371/journal.pone.0227914Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe.Alessandro ArmuzziMarco daCosta DiBonaventuraMiriam TaralloJames LucasDaniel BluffBenjamin HoskinDanielle BargoJoseph C CappelleriDaniel QuirkLeonardo SaleseOBJECTIVE:The aim of the present study is to examine how moderate-to-severe ulcerative colitis (UC) is currently managed in real-world clinical practice across the United States (US) and European Union Five (EU5; France, Germany, Italy, Spain, and the United Kingdom). METHODS:Data from the 2017 Adelphi Inflammatory Bowel-Disease Specific Programme (IBD-DSP) were used. The IBD-DSP is a database of patient chart information abstracted by selected gastroenterologists across the US and EU5. Eligible gastroenterologists who agreed to participate were asked to complete patient record forms for the next seven consecutive eligible adult patients with UC. Only charts from patients with moderate-to-severe UC were included in the analysis (defined as those with documented administration of either an immunosuppressant [IM] or a biologic). Treatment patterns were reported descriptively. RESULTS:411 and 1191 patient charts were included in the US and EU5 (mean ages 44.2 and 39.6 years; 53.0% and 43.5% female), respectively. For those with complete treatment history, 40.7% and 52.9% used either an IM or biologic as their first treatment (with or without steroids). Usage of these therapies increased in subsequent lines. The percentage of patients treated with combination therapy (i.e., biologic therapy with a concomitant IM) in first line generally varied between 10-20% (e.g., US: adalimumab (ADA), 10.8%; infliximab (IFX), 18.2%; EU5: ADA, 12.5%; IFX, 19.9%), though increased in later lines in the EU5. Among patients currently using a biologic therapy, between 10-40% of patients used a higher than indicated dose or greater than indicated dosing frequency during maintenance (e.g., US: IFX, 37.1%; ADA, 13.4%; EU5: IFX, 39.1%; ADA, 36.1%). In both the US and EU5, the primary reason for switching therapy was efficacy-related. CONCLUSIONS:In this analysis, many patients with moderate-to-severe UC use an IM or biologic as their first therapy after diagnosis. Combination therapy and dose escalation are also common, and underscore the challenges with managing this patient population.https://doi.org/10.1371/journal.pone.0227914 |
| spellingShingle | Alessandro Armuzzi Marco daCosta DiBonaventura Miriam Tarallo James Lucas Daniel Bluff Benjamin Hoskin Danielle Bargo Joseph C Cappelleri Daniel Quirk Leonardo Salese Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS ONE |
| title | Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. |
| title_full | Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. |
| title_fullStr | Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. |
| title_full_unstemmed | Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. |
| title_short | Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. |
| title_sort | treatment patterns among patients with moderate to severe ulcerative colitis in the united states and europe |
| url | https://doi.org/10.1371/journal.pone.0227914 |
| work_keys_str_mv | AT alessandroarmuzzi treatmentpatternsamongpatientswithmoderatetosevereulcerativecolitisintheunitedstatesandeurope AT marcodacostadibonaventura treatmentpatternsamongpatientswithmoderatetosevereulcerativecolitisintheunitedstatesandeurope AT miriamtarallo treatmentpatternsamongpatientswithmoderatetosevereulcerativecolitisintheunitedstatesandeurope AT jameslucas treatmentpatternsamongpatientswithmoderatetosevereulcerativecolitisintheunitedstatesandeurope AT danielbluff treatmentpatternsamongpatientswithmoderatetosevereulcerativecolitisintheunitedstatesandeurope AT benjaminhoskin treatmentpatternsamongpatientswithmoderatetosevereulcerativecolitisintheunitedstatesandeurope AT daniellebargo treatmentpatternsamongpatientswithmoderatetosevereulcerativecolitisintheunitedstatesandeurope AT josephccappelleri treatmentpatternsamongpatientswithmoderatetosevereulcerativecolitisintheunitedstatesandeurope AT danielquirk treatmentpatternsamongpatientswithmoderatetosevereulcerativecolitisintheunitedstatesandeurope AT leonardosalese treatmentpatternsamongpatientswithmoderatetosevereulcerativecolitisintheunitedstatesandeurope |